CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 6, 2012--
Headline of release should read: Idera Pharmaceuticals to Present at BIO
CEO Conference February 13th, 2012 (sted Idera
Pharmaceuticals to Present at BIO CEO Conference February 14th,
2012)
The corrected release reads:
IDERA PHARMACEUTICALS TO PRESENT AT BIO CEO CONFERENCE FEBRUARY 13TH,
2012
Idera Pharmaceuticals (Nasdaq: IDRA) today announced that Sudhir
Agrawal, D.Phil., Chairman and Chief Executive Officer, is scheduled to
present at the 14th Annual BIO CEO & Investor Conference on
February 13th at 10:30 am ET. Dr. Agrawal will provide a
review of Idera's Toll-like Receptor-targeted development programs in
oncology and autoimmune diseases as well as its gene silencing
oligonucleotide (GSO) technology.
The live webcast of the presentation will be available in the Investor
section of Idera's website: www.iderapharma.com.
An archived version will also be available on the Company's website
after the event for a limited time. Please log in approximately 10
minutes prior to the presentation to ensure a timely connection.
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals applies its proprietary Toll-like Receptor (TLR)
drug discovery platform to create immunomodulatory drug candidates. The
Company's TLR-targeted candidates are being developed to treat
autoimmune and inflammatory diseases and cancer, and for use as vaccine
adjuvants. Additionally, the Company is advancing its gene-silencing
oligonucleotide (GSO) technology for the purpose of inhibiting the
expression of disease-promoting genes. For more information, visit http://www.iderapharma.com.
Source: Idera Pharmaceuticals
Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
larcudi@iderapharma.com
or
MacDougall
Biomedical Communications
Chris Erdman, 781-235-3060
cerdman@macbiocom.com
